Juno licenses IP from OncoTracker, Fred Hutchinson
Executive Summary
Biomarker firm OncoTracker Inc. and the Fred Hutchinson Cancer Research Center have each granted Juno Therapeutics Inc. exclusive intellectual property rights related to the combination of gamma-secretase inhibitors (GSIs) with B-cell maturation antigen (BCMA)-directed engineered T-cells for the treatment of multiple myeloma.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice